Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis acquires Mexican firm

This article was originally published in The Tan Sheet

Executive Summary

The Paris-based firm acquires Laboratorios Kendrick and plans to fold the generics firm into its existing Mexican generics business. The April 2 deal gives Sanofi more than 50 active pharmaceutical ingredients in Kendrick's portfolio, including the antihistamine loratadine. Kendrick's sales reached around 500 million pesos in 2008. Sanofi also expanded its global OTC business with the recent acquisition of Czech firm Zentiva (1"The Tan Sheet" Feb. 16, 2009, p. 6)

You may also be interested in...

Sanofi continues Latin American swing

Sanofi-Aventis acquires Brazilian generic drug maker Medley, which it values at 500 million Euros ($662.3 million by April 10 conversion rates). The addition of Medley's 127 generic products, including OTC drugs, will make Sanofi the No. 1 pharma company in Brazil, with 12 percent market share, the Paris-based firm said in an April 9 release. Medley's 2008 sales reached $202.7 million. Sanofi added it expects Brazil's generics market to grow 20 percent annually in the coming years. The firm reached into Brazil a week after acquiring Mexican generics firm Laboratorios Kendrick (1"The Tan Sheet" April 6, 2009, In Brief)

Sanofi-Aventis Acquisitions Could Double OTC Sales By 2014

French drug maker Sanofi-Aventis is establishing an OTC division and plans to double revenues from nonprescription drug products within five years

Warning Letter Close-Outs – March 2020

The US FDA released five device-related close-out letters in March.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts